A Phase 2a Clinical Trial of of VAR 200 (2-hydroxypropyl-ß-cyclodextrin, or HPßCD) in Adult Patients with Focal Segmental Glomerulosclerosis (FSGS)
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2019
Price : $35 *
At a glance
- Drugs Hydroxypropyl betadex (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Therapeutic Use
- Sponsors ZyVersa Therapeutics
- 25 Sep 2019 According to an ZyVersa Therapeutics media release, this study is expected to be initiated by end of 2019.
- 03 Dec 2018 According to a Variant Pharmaceuticals media release, the company has secured $10 Million in financing from Korean company, Incon, in exchange for equity ownership. The funding will be used for the execution of this trial.
- 24 Oct 2018 New trial record